Business not as usual
The coronavirus outbreak is expected to trigger big economic and political changes that will inevitably affect major parts of the global chemical industry, reports Sean Milmo
Biomedical
This Biomedical Highlights column features an aspect of target validation for the coronaviruses and crowned by the SARS-CoV-2 spike protein operative in Covid-19.
Ups and downs
Mixed fortunes for lab equipment producers have reduced the number of new kit launches, Neil Eisberg reports
Trace element challenge
As the environmental testing market continues to grow, laboratories will need to make suitable technological upgrades to meet this huge wave of demand.
Innovation in lockdown
Few people could have anticipated the impact of Covid-19. Apart from the economic and health impacts, the working environment has completely changed. Governments advised people to work from home and left business leaders worried about the impact on their organisations.
Niger polio outbreak
Niger has become the 15th country in Africa to report an outbreak of the circulated vaccine-derived poliovirus (cVDPV), according to the World Health Organization (WHO).
Next generation Alzheimer’s drug
Despite overwhelming genetic evidence to support the involvement of the AB protein in the pathology of Alzheimer’s Disease (AD), previous efforts targeting the protein have led to many disappointing clinical trial failures.
Gene therapy shake-up
The past year has seen several positive developments on the gene therapy front, according to experts at the digital BIO meeting in June 2020.
Big nanocar race
Teams are gearing up for the next nanocar Grand Prix, with ten entrants prepping nano vehicles for the Race in Toulouse in 2021. Now, scientists in Japan and France have reported a new family of nanocars ahead of the big event.